Given that this patient's mesenteric plexiform neurofibroma is associated with <i>YPEL3</i> dysfunction, she is unlikely to benefit from MEK inhibitors, which are the newly approved treatment for inoperable plexiform neurofibroma in patients with neurofibromatosis type 1. This evidence concerns the gene MAP2K7 and plexiform neurofibroma.